Transforming growth factor-β signaling in normal and malignant hematopoiesis

Journal of Interferon and Cytokine Research

Volumn 27, Issue 7, 2007, Pages 543-552

  Isufi, Iris ^a   Seetharam, Mahesh ^a   Zhou, Li ^a   Sohal, Davendra ^a   Opalinska, Joanna ^a   Pahanish, Perry ^a   Verma, Amit ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA RECEPTOR;

BONE MARROW CELL; CELL DIFFERENTIATION; CELL GROWTH; ERYTHROID CELL; HEMATOLOGIC DISEASE; HEMATOPOIESIS; HEMATOPOIETIC STEM CELL; HUMAN; MALIGNANT NEOPLASTIC DISEASE; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION; TUMOR GROWTH;

ANIMALS; APOPTOSIS; HEMATOPOIESIS; HUMANS; LEUKEMIA; LYMPHOMA; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROMES; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; SIGNAL TRANSDUCTION; TRANSFORMING GROWTH FACTOR BETA;

EID: 34547160194     PISSN: 10799907     EISSN: None     Source Type: Journal    
DOI: 10.1089/jir.2007.0009     Document Type: Review

References (102)

1. Lawrence DA. Identification and activation of latent transforming growth factor beta. Methods Enzymol. 1991;198:327-336.
2. Oklu R, Hesketh R. The latent transforming growth factor beta binding protein (LTBP) family. Biochem. J. 2000;352: 601-610.
3. Gleizes PE, Munger JS, Nunes I, Harpel JG, Mazzieri R, Noguera I, Rifkin DB. TGF-beta latency: biological significance and mechanisms of activation. Stem Cells 1997;15:190-197.
4. Yu Q, Stamenkovic I. Cell surface-localized matrix metalloproteinase-9 proteolytically activates TGF-beta and promotes tumor invasion and angiogenesis. Genes Dev. 2000;14:163-176.
5. Lyons RM, Gentry LE, Purchio AF, Moses HL. Mechanism of activation of latent recombinant transforming growth factor beta 1 by plasmin. J. Cell. Biol. 1990;110:1361-1367.
6. Crawford SE, Stellmach V, Murphy-Ullrich JE, Ribeiro SM, Lawler J, Hynes RO, Boivin GP, Bouck N. Thrombospondin-1 is a major activator of TGF-beta1 in vivo. Cell 1998;93: 1159-1170.
7. Schultz-Cherry S, Lawler J, Murphy-Ullrich JE. The type 1 repeats of thrombospondin 1 activate latent transforming growth factor-beta. J. Biol. Chem. 1994;269:26783-26788.
8. Wrana JL, Attisano L, Wieser R, Ventura F, Massague J. Mechanism of activation of the TGF-beta receptor. Nature 1994;370: 341-347.
9. Lopez-Casillas F, Wrana JL, Massague J. Betaglycan presents ligand to the TGF beta signaling receptor. Cell 1993;73:1435-1444.
10. Fortunel NO, Hatzfeld A, Hatzfeld JA. Transforming growth factor-beta: pleiotropic role in the regulation of hematopoiesis. Blood 2000;96:2022-2036.
11. Wrana JL, Attisano L, Carcamo J, Zentella A, Doody J, Laiho M, Wang XF, Massague J. TGF beta signals through a heteromeric protein kinase receptor complex. Cell 1992;71:1003-1014.
12. Piek E, Heldin CH, Ten Dijke P. Specificity, diversity, and regulation in TGF-beta superfamily signaling. FASEB J. 1999;13: 2105-2124.
13. Massague J. TGF-beta signal transduction. Annu. Rev. Biochem. 1998;67:753-791.
14. Zawel L, Dai JL, Buckhaults P, Zhou S, Kinzler KW, Vogelstein B, Kern SE. Human Smad3 and Smad4 are sequence-specific transcription activators. Mol. Cell 1998;1:611-617.
15. ten Dijke P, Miyazono K, Heldin CH. Signaling inputs converge on nuclear effectors in TGF-beta signaling. Trends Biochem. Sci. 2000;25:64-70.
16. Attisano L, Wrana JL. Smads as transcriptional co-modulators. Curr. Opin. Cell. Biol. 2000;12:235-243.
17. Zhang Y, Derynck R. Regulation of Smad signalling by protein associations and signalling crosstalk. Trends Cell. Biol. 1999;9: 274-279.
18. Shi Y, Massague J. Mechanisms of TGF-beta signaling from cell membrane to the nucleus. Cell 2003;113:685-700.
19. Macias-Silva M, Abdollah S, Hoodless PA, Pirone R, Attisano L, Wrana JL. MADR2 is a substrate of the TGFbeta receptor and its phosphorylation is required for nuclear accumulation and signaling. Cell 1996;87:1215-1224.
20. Nakao A, Imamura T, Souchelnytskyi S, Kawabata M, Ishisaki A, Oeda E, Tamaki K, Hanai J, Heldin CH, Miyazono K, ten Dijke P. TGF-beta receptor-mediated signalling through Smad2, Smad3 and Smad4. EMBO J. 1997;16:5353-5362.
21. Zhu HJ, Iaria J, Sizeland AM. Smad7 differentially regulates transforming growth factor beta-mediated signaling pathways. J. Biol. Chem. 1999;274:32258-32264.
22. Nagarajan RP, Zhang J, Li W, Chen Y. Regulation of Smad7 promoter by direct association with Smad3 and Smad4. J. Biol. Chem. 1999;274:33412-34418.
23. Fautsch MP, Eblen ST, Anders RA, Burnette RJ, Leof EB. Differential regulation of p34cdc2 and p33cdk2 by transforming growth factor-beta 1 in murine mammary epithelial cells. J. Cell. Biochem. 1995;58:517-526.
24. Geng Y, Weinberg RA. Transforming growth factor beta effects on expression of G1 cyclins and cyclin-dependent protein kinases. Proc. Natl. Acad. Sci. USA 1993;90:10315-10319.
25. Hu X, Zuckerman KS. Transforming growth factor: signal transduction pathways, cell cycle mediation, and effects on hematopoiesis. J. Hematother. Stem Cell Res. 2001;10:67-74.
26. Bhatia M, Bonnet D, Wu D, Murdoch B, Wrana J, Gallacher L, Dick JE. Bone morphogenetic proteins regulate the developmental program of human hematopoietic stem cells. J. Exp. Med. 1999;189:1139-1148.
27. Bruno E, Horrigan SK, Van Den Berg D, Rozler E, Fitting PR, Moss ST, Westbrook C, Hoffman R. The Smad5 gene is involved in the intracellular signaling pathways that mediate the inhibitory effects of transforming growth factor-beta on human hematopoiesis. Blood 1998;91:1917-1923.
28. Massague J, Chen YG. Controlling TGF-beta signaling. Genes Dev. 2000;14:627-644.
29. Remy I, Montmarquette A, Michnick SW. PKB/Akt modulates TGF-beta signalling through a direct interaction with Smad3. Nat. Cell Biol. 2004;6:358-365.
30. Verma A, Deb DK, Sassano A, Uddin S, Varga J, Wickrema A, Platanias LC. Activation of the p38 mitogen-activated protein kinase mediates the suppressive effects of type I interferons and transforming growth factor-beta on normal hematopoiesis. J. Biol. Chem. 2002;277:7726-7735.
31. Keller JR, Mantel C, Sing GK, Ellingsworth LR, Ruscetti SK, Ruscetti FW. Transforming growth factor beta 1 selectively regulates early murine hematopoietic progenitors and inhibits the growth of IL-3-dependent myeloid leukemia cell lines. J. Exp. Med. 1988;168:737-750.
32. Ohta M, Greenberger JS, Anklesaria P, Bassols A, Massague J. Two forms of transforming growth factor-beta distinguished by multipotential haematopoietic progenitor cells. Nature 1987;329: 539-541.
33. Sargiacomo M, Valtieri M, Gabbianelli M, Pelosi E, Testa U, Camagna A, Peschle C. Pure human hematopoietic progenitors: direct inhibitory effect of transforming growth factors-beta 1 and - beta 2. Ann. NY Acad. Sci. 1991;628:84-91.
34. Sing GK, Keller JR, Ellingsworth LR, Ruscetti FW. Transforming growth factor beta selectively inhibits normal and leukemic human bone marrow cell growth in vitro. Blood 1988;72: 1504-1511.
35. Keller JR, McNiece IK, Sill KT, Ellingsworth LR, Quesenberry PJ, Sing GK, Ruscetti FW. Transforming growth factor beta directly regulates primitive murine hematopoietic cell proliferation. Blood 1990;75:596-602.
36. Fan X, Valdimarsdottir G, Larsson J, Brun A, Magnusson M, Jacobsen SE, ten Dijke P, Karlsson S. Transient disruption of autocrine TGF-beta signaling leads to enhanced survival and proliferation potential in single primitive human hemopoietic progenitor cells. J. Immunol. 2002;168:755-762.
37. Larsson J, Blank U, Helgadottir H, Bjornsson JM, Ehinger M, Goumans MJ, Fan X, Leveen P, Karlsson S. TGF-beta signaling-deficient hematopoietic stem cells have normal self-renewal and regenerative ability in vivo despite increased proliferative capacity in vitro. Blood 2003;102:3129-3135.
38. Jacobsen FW, Stokke T, Jacobsen SE. Transforming growth factor-beta potently inhibits the viability-promoting activity of stem cell factor and other cytokines and induces apoptosis of primitive murine hematopoietic progenitor cells. Blood 1995;86:2957-2966.
39. Sitnicka E, Ruscetti FW, Priestley GV, Wolf NS, Bartelmez SH. Transforming growth factor beta 1 directly and reversibly inhibits the initial cell divisions of long-term repopulating hematopoietic stem cells. Blood 1996;88:82-88.
40. Goey H, Keller JR, Back T, Longo DL, Ruscetti FW, Wiltrout RH. Inhibition of early murine hemopoietic progenitor cell proliferation after in vivo locoregional administration of transforming growth factor-beta 1. J. Immunol. 1989;143:877-880.
41. Kulkarni AB, Huh CG, Becker D, Geiser A, Lyght M, Flanders KC, Roberts AB, Sporn MB, Ward JM, Karlsson S. Transforming growth factor beta 1 null mutation in mice causes excessive inflammatory response and early death. Proc. Natl. Acad. Sci. USA 1993;90:770-774.
42. Shull MM, Ormsby I, Kier AB, Pawlowski S, Diebold RJ, Yin M, Allen R, Sidman C, Proetzel G, Calvin D, et al. Targeted disruption of the mouse transforming growth factor-beta 1 gene results in multifocal inflammatory disease. Nature 1992;359: 693-699.
43. Dickson MC, Martin JS, Cousins FM, Kulkarni AB, Karlsson S, Akhurst RJ. Defective haematopoiesis and vasculogenesis in transforming growth factor-beta 1 knock out mice. Development 1995;121:1845-1854.
44. Oshima M, Oshima H, Taketo MM. TGF-beta receptor type II deficiency results in defects of yolk sac hematopoiesis and vasculogenesis. Dev. Biol. 1996;179:297-302.
45. Ottmann OG, Pelus LM. Differential proliferative effects of transforming growth factor-beta on human hematopoietic progenitor cells. J. Immunol. 1988;140:2661-2665.
46. Keller JR, Jacobsen SE, Sill KT, Ellingsworth LR, Ruscetti FW. Stimulation of granulopoiesis by transforming growth factor beta: synergy with granulocyte/macrophage-colony-stimulating factor. Proc. Natl. Acad. Sci. USA 1991;88:7190-7194.
47. Krystal G, Lam V, Dragowska W, Takahashi C, Appel J, Gontier A, Jenkins A, Lam H, Quon L, Lansdorp P. Transforming growth factor beta 1 is an inducer of erythroid differentiation. J. Exp. Med. 1994;180:851-860.
48. He W, Dorn DC, Erdjument-Bromage H, Tempst P, Moore MA, Massague J. Hematopoiesis controlled by distinct TIF1gamma and Smad4 branches of the TGFbeta pathway. Cell 2006;125: 929-941.
49. Berthier R, Valiron O, Schweitzer A, Marguerie G. Serum-free medium allows the optimal growth of human megakaryocyte progenitors compared with human plasma supplemented cultures: role of TGF beta. Stem Cells 1993;11:120-129.
50. Jackson H, Williams N, Westcott KR, Green R. Differential effects of transforming growth factor-beta 1 on distinct developmental stages of murine megakaryocytopoiesis. J. Cell. Physiol. 1994;161:312-318.
51. Kuter DJ, Gminski DM, Rosenberg RD. Transforming growth factor beta inhibits megakaryocyte growth and endomitosis. Blood 1992;79:619-626.
52. Wierenga AT, Eggen BJ, Kruijer W, Vellenga E. Proteolytic degradation of Smad4 in extracts of AML blasts. Leuk. Res. 2002; 26:1105-1111.
53. Imai Y, Kurokawa M, Izutsu K, Hangaishi A, Maki K, Ogawa S, Chiba S, Mitani K, Hirai H. Mutations of the Smad4 gene in acute myelogeneous leukemia and their functional implications in leukemogenesis. Oncogene 2001;20:88-96.
54. Wolfraim LA, Fernandez TM, Mamura M, Fuller WL, Kumar R, Cole DE, Byfield S, Felici A, Flanders KC, Walz TM, Roberts AB, Aplan PD, Balis FM, Letterio JJ. Loss of Smad3 in acute T-cell lymphoblastic leukemia. N Engl. J. Med. 2004;351:552-559.
55. Jakubowiak A, Pouponnot C, Berguido F, Frank R, Mao S, Massague J, Nimer SD. Inhibition of the transforming growth factor beta 1 signaling pathway by the AML1/ETO leukemia-associated fusion protein. J. Biol. Chem. 2000;275:40282-40287.
56. Lin HK, Bergmann S, Pandolfi PP. Cytoplasmic PML function in TGF-beta signaling. Nature 2004;431:205-211.
57. Izutsu K, Kurokawa M, Imai Y, Maki K, Mitani K, Hirai H. The corepressor CtBP interacts with Evi-1 to repress transforming growth factor beta signaling. Blood 2001;97:2815-2822.
58. Lee DK, Kim BC, Brady JN, Jeang KT, Kim SJ. Human T-cell lymphotropic virus type 1 tax inhibits transforming growth factor-beta signaling by blocking the association of Smad proteins
59. with Smad-binding element. J. Biol. Chem. 2002;277:33766-33775.
60. Mori N, Morishita M, Tsukazaki T, Giam CZ, Kumatori A, Tanaka Y, Yamamoto N. Human T-cell leukemia virus type I oncoprotein Tax represses Smad-dependent transforming growth factor beta signaling through interaction with CREB-binding protein/p300. Blood 2001;97:2137-2144.
61. Inman GJ, Allday MJ. Resistance to TGF-beta1 correlates with a reduction of TGF-beta type II receptor expression in Burkitt's lymphoma and Epstein-Barr virus-transformed B lymphoblastoid cell lines. J. Gen. Virol. 2000;81:1567-1578.
62. Gruss HJ, Herrmann F, Drexler HG. Hodgkin's disease: a cytokine-producing tumor - a review. Crit. Rev. Oncog. 1994;5: 473-538.
63. Hsu SM, Lin J, Xie SS, Hsu PL, Rich S. Abundant expression of transforming growth factor-beta 1 and -beta 2 by Hodgkin's Reed-Sternberg cells and by reactive T lymphocytes in Hodgkin's disease. Hum. Pathol. 1993;24:249-255.
64. Woszczyk D, Gola J, Jurzak M, Mazurek U, Mykala-Ciesla J, Wilczok T. Expression of TGF beta1 genes and their receptor types I, II, and III in low- and high-grade malignancy non-Hodgkin's lymphomas. Med. Sci. Monit. 2004;10:CR33-37.
65. Kadin ME, Cavaille-Coll MW, Gertz R, Massague J, Cheifetz S, George D. Loss of receptors for transforming growth factor beta in human T-cell malignancies. Proc. Natl. Acad. Sci. USA 1994;91:6002-6006.
66. Capocasale RJ, Lamb RJ, Vonderheid EC, Fox FE, Rook AH, Nowell PC, Moore JS. Reduced surface expression of transforming growth factor beta receptor type II in mitogen-activated T cells from Sezary patients. Proc. Natl. Acad. Sci. USA 1995;92: 5501-5505.
67. Schiemann WP, Pfeifer WM, Levi E, Kadin ME, Lodish HF. A deletion in the gene for transforming growth factor beta type I receptor abolishes growth regulation by transforming growth factor beta in a cutaneous T-cell lymphoma. Blood 1999;94:2854-2861.
68. Amoroso SR, Huang N, Roberts AB, Potter M, Letterio JJ. Consistent loss of functional transforming growth factor beta receptor expression in murine plasmacytomas. Proc. Natl. Acad. Sci. USA 1998;95:189-194.
69. Fernandez T, Amoroso S, Sharpe S, Jones GM, Bliskovski V, Kovalchuk A, Wakefield LM, Kim SJ, Potter M, Letterio JJ. Disruption of transforming growth factor beta signaling by a novel ligand-dependent mechanism. J. Exp. Med. 2002;195:1247-1255.
70. Urashima M, Ogata A, Chauhan D, Hatziyanni M, Vidriales MB, Dedera DA, Schlossman RL, Anderson KC. Transforming growth factor-beta1: differential effects on multiple myeloma versus normal B cells. Blood 1996;87:1928-1938.
71. Dankbar B, Padro T, Leo R, Feldmann B, Kropff M, Mesters RM, Serve H, Berdel WE, Kienast J. Vascular endothelial growth factor and interleukin-6 in paracrine tumor-stromal cell interactions in multiple myeloma. Blood 2000;95:2630-2636.
72. Masuya M, Kita K, Shimizu N, Ohishi K, Katayama N, Sekine T, Otsuji A, Miwa H, Shirakawa S. Biologic characteristics of acute leukemia after myelodysplastic syndrome. Blood 1993;81: 3388-3394.
73. Sood R, Talwar-Trikha A, Chakrabarti SR, Nucifora G. MDS1/EVI1 enhances TGF-betal signaling and strengthens its growth-inhibitory effect but the leukemia-associated fusion protein AML1/MDS1/EVI1, product of the t(3;21), abrogates growth-inhibition in response to TGF-beta1. Leukemia 1999;13:348-357.
74. Heaney ML, Golde DW. Myelodysplasia. N. Engl. J. Med. 1999;340:1649-1660.
75. Zorat F, Shetty V, Dutt D, Lisak L, Nascimben F, Allampallam K, Dar S, York A, Gezer S, Venugopal P, Raza A. The clinical and biological effects of thalidomide in patients with myelodysplastic syndromes. Br. J. Haematol. 2001;115:881-894.
76. Allampallam K, Shetty V, Mundle S, Dutt D, Kravitz H, Reddy PL, Alvi S, Galili N, Saberwal GS, Anthwal S, Shaikh MW, York A, Raza A. Biological significance of proliferation, apoptosis, cytokines, and monocyte/macrophage cells in bone marrow biopsies of 145 patients with myelodysplastic syndrome. Int. J. Hematol. 2002;75:289-297.
77. Verma A, Mohindru M, Deb DK, Sassano A, Kambhampati S, Ravandi F, Minucci S, Kalvakolanu DV, Platanias LC. Activation of Rac1 and the p38 mitogen-activated protein kinase pathway in response to arsenic trioxide. J. Biol. Chem. 2002; 277:44988-44995.
78. Navas TA, Mohindru M, Estes M, Ma JY, Sokol L, Pahanish P, Parmar S, Haghnazari E, Zhou L, Collins R, Kerr I, Nguyen AN, Xu Y, Platanias LC, List AA, Higgins LS, Verma A. Inhibition of overactivated p38 MAPK can restore hematopoiesis in myelodysplastic syndrome progenitors. Blood 2006;108:4170-4177.
79. 1 to S transition, but not activation of human B lymphocytes. Exp. Cell Res. 1987;171:213-222.
80. Chaouchi N, Arvanitakis L, Auffredou MT, Blanchard DA, Vazquez A, Sharma S. Characterization of transforming growth factor-beta 1 induced apoptosis in normal human B cells and lymphoma B cell lines. Oncogene 1995;11:1615-1622.
81. Altiok A, Bejarano MT, Klein G, Klein E. Effect of TGF-beta 1 on the EBV-induced transformation of human lymphocyte cultures. Int. J. Cancer 1992;50:772-776.
82. Lebman DA, Edmiston JS. The role of TGF-beta in growth, differentiation, and maturation of B lymphocytes. Microbes Infect. 1999;1:1297-1304.
83. Blomhoff HK, Smeland E, Mustafa AS, Godal T, Ohlsson R. Epstein-Barr virus mediates a switch in responsiveness to trans forming growth factor, type beta, in cells of the B cell lineage. Eur. J. Immunol. 1987;17:299-301.
84. Kehrl JH, Roberts AB, Wakefield LM, Jakowlew S, Sporn MB, Fauci AS. Transforming growth factor beta is an important immunomodulatory protein for human B lymphocytes. J. Immunol. 1986;137:3855-3860.
85. Kumar A, Rogers T, Maizel A, Sharma S. Loss of transforming growth factor beta 1 receptors and its effects on the growth of EBV-transformed human B cells. J. Immunol. 1991;147: 998-1006.
86. Gregory CD, Dive C, Henderson S, Smith CA, Williams GT, Gordon J, Rickinson AB. Activation of Epstein-Barr virus latent genes protects human B cells from death by apoptosis. Nature 1991;349: 612-614.
87. Hasbold J, Klaus GG. Anti-immunoglobulin antibodies induce apoptosis in immature B cell lymphomas. Eur. J. Immunol. 1990; 20:1685-1690.
88. Beckwith M, Ruscetti FW, Sing GK, Urba WJ, Longo DL. Anti-IgM induces transforming growth factor-beta sensitivity in a human B-lymphoma cell line: inhibition of growth is associated with a downregulation of mutant p53. Blood 1995;85:2461-2470.
89. MacDonald I, Wang H, Grand R, Armitage RJ, Fanslow WC, Gregory CD, Gordon J. Transforming growth factor-beta 1 cooperates with anti-immunoglobulin for the induction of apoptosis in group I (biopsy-like) Burkitt lymphoma cell lines. Blood 1996;87:1147-1154.
90. Inman GJ, Allday MJ. Apoptosis induced by TGF-beta 1 in Burkitt's lymphoma cells is caspase 8 dependent but is death receptor independent. J. Immunol. 2000;165:2500-2510.
91. Schrantz N, Bourgeade MF, Mouhamad S, Leca G, Sharma S, Vazquez A. p38-mediated regulation of a Fas-associated death domain protein-independent pathway leading to caspase-8 activation during TGFbeta-induced apoptosis in human Burkitt lym phoma B cells BL41. Mol. Biol. Cell. 2001;12:3139-3151.
92. Maesako Y, Uchiyama T, Ohno H. Comparison of gene expression profiles of lymphoma cell lines from transformed follicular lymphoma, Burkitt's lymphoma and de novo diffuse large B-cell lymphoma. Cancer Sci. 2003;94:774-781.
93. Munoz O, Fend F, de Beaumont R, Husson H, Astier A, Freedman AS. TGFbeta-mediated activation of Smad1 in B-cell non-Hodgkin's lymphoma and effect on cell proliferation. Leukemia 2004;18:2015-2025.
94. Dong M, Blobe GC. Role of transforming growth factor-beta in hematologic malignancies. Blood 2006;107:4589-4596.
95. Mazur G, Bogunia-Kubik K, Wrobel T, Kuliczkowski K, Lange A. TGF-beta1 gene polymorphisms influence the course of the disease in non-Hodgkin's lymphoma patients. Cytokine 2006;33: 145-149.
96. Kehrl JH, Wakefield LM, Roberts AB, Jakowlew S, Alvarez-Mon M, Derynck R, Sporn MB, Fauci AS. Production of transforming growth factor beta by human T lymphocytes and its potential role in the regulation of T cell growth. J. Exp. Med. 1986;163: 1037-1050.
97. Berger CL, Hanlon D, Kanada D, Dhodapkar M, Lombillo V, Wang N, Christensen I, Howe G, Crouch J, El-Fishawy P, Edelson R. The growth of cutaneous T-cell lymphoma is stimulated by immature dendritic cells. Blood 2002;99:2929-2939.
98. Levings MK, Bacchetta R, Schulz U, Roncarolo MG. The role of IL-10 and TGF-beta in the differentiation and effector function of T regulatory cells. Int. Arch. Allergy Immunol. 2002;129: 263-276.
99. + precursor cells develop into Langerhans cells in a TGF-beta 1-dependent manner. J. Immunol. 1999;163:4869-4877.
100. Berger CL, Tigelaar R, Cohen J, Mariwalla K, Trinh J, Wang N, Edelson RL. Cutaneous T-cell lymphoma: malignant proliferation of T-regulatory cells. Blood 2005;105:1640-1647.
101. Klein B, Zhang XG, Jourdan M, Content J, Houssiau F, Aarden L, Piechaczyk M, Bataille R. Paracrine rather than autocrine regulation of myeloma-cell growth and differentiation by interleukin-6. Blood 1989;73:517-526.
102. Hayashi T, Hideshima T, Nguyen AN, Munoz O, Podar K, Hamasaki M, Ishitsuka K, Yasui H, Richardson P, Chakravarty S, Murphy A, Chauhan D, Higgins LS, Anderson KC. Transforming growth factor beta receptor I kinase inhibitor down-regulates cytokine secretion and multiple myeloma cell growth in the bone marrow microenvironment. Clin. Cancer Res. 2004;10: 7540-7546.